Mitral Regurgitation III: Medical Management

Treatment depends on mitral regurgitation severity, symptoms, and underlying cause. Mild or moderate MR typically requires regular monitoring without immediate intervention. Severe MR necessitates pharmacological management to control symptoms and prevent complications. Monitoring frequency increases with severity: mild MR warrants echocardiograms every 3-5 years, moderate MR every 1-2 years, and severe MR every 6-12 months.

Diuretics relieve fluid overload and pulmonary edema in severe MR. ACE inhibitors and angiotensin II receptor blockers reduce cardiac afterload and slow left ventricular dysfunction progression. Beta-blockers control heart rate and improve cardiac output efficiency. Anticoagulants are prescribed for patients with atrial fibrillation to prevent thromboembolic events, including stroke.

Surgical intervention becomes necessary when heart failure symptoms persist despite pharmacological management. Options include annuloplasty, which reinforces the valve annulus with a ring to improve closure; valvuloplasty for narrowed valves; mitral valve clip placement for edge-to-edge repair; or mitral valve replacement with mechanical or tissue valves when repair is impossible.

ACE inhibitors and angiotensin II receptor blockers reduce cardiac afterload by relaxing blood vessels, decreasing the volume of regurgitant blood flow back into the left atrium. These medications slow the progression of left ventricular dysfunction, a key complication of chronic mitral regurgitation, helping preserve heart function over time.

A low-sodium diet helps manage mitral regurgitation symptoms by reducing fluid retention and decreasing cardiac workload. Physical activity should be moderated or limited if symptoms develop, such as shortness of breath or fatigue. These modifications complement pharmacological treatment and help prevent disease progression in mild to moderate cases.

Annuloplasty reinforces the mitral valve annulus with a flexible ring to restore proper valve closure and reduce regurgitation while preserving the native valve. Mitral valve replacement removes the damaged valve entirely and substitutes a mechanical or tissue valve, eliminating regurgitation completely. Replacement is necessary when the valve cannot be repaired.

Atrial fibrillation often accompanies mitral regurgitation and increases thromboembolic risk due to irregular heart rhythm and blood stasis in the left atrium. Anticoagulants prevent blood clot formation and reduce the risk of stroke and other thromboembolic events in these patients, making anticoagulation a critical component of medical management.